PortalPublikationenClinical impact of FLT3 mutation load in acute promyelocytic...

Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.

Standard

Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA. / Schnittger, Susanne; Bacher, Ulrike; Haferlach, Claudia; Kern, Wolfgang; Alpermann, Tamara; Haferlach, Torsten.

in: HAEMATOLOGICA, Jahrgang 96, Nr. 12, 12, 2011, S. 1799-1807.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Schnittger, S, Bacher, U, Haferlach, C, Kern, W, Alpermann, T & Haferlach, T 2011, 'Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.', HAEMATOLOGICA, Jg. 96, Nr. 12, 12, S. 1799-1807. https://doi.org/10.3324/haematol.2011.049007

APA

Schnittger, S., Bacher, U., Haferlach, C., Kern, W., Alpermann, T., & Haferlach, T. (2011). Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA. HAEMATOLOGICA, 96(12), 1799-1807. [12]. https://doi.org/10.3324/haematol.2011.049007

Vancouver

Schnittger S, Bacher U, Haferlach C, Kern W, Alpermann T, Haferlach T. Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA. HAEMATOLOGICA. 2011;96(12):1799-1807. 12. https://doi.org/10.3324/haematol.2011.049007

Bibtex

@article{52cea8067ebb4b4197c2b470c9e82fc3,
title = "Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.",
abstract = "Combined treatment with all-trans-retinoic acid and chemotherapy is extremely efficient in patients with acute promyelocytic leukemia with t(15;17)/PML-RARA, but up to 15% of patients relapse.",
keywords = "Adult, Humans, Male, Aged, Female, Middle Aged, Survival Rate, Disease-Free Survival, Antineoplastic Agents/administration & dosage, Chromosomes, Human, Pair 15/*genetics, Chromosomes, Human, Pair 17/*genetics, Leukemia, Promyelocytic, Acute/drug therapy/*genetics/*mortality, Oncogene Proteins, Fusion/*genetics, *Translocation, Genetic, Tretinoin/administration & dosage, fms-Like Tyrosine Kinase 3/*genetics, Adult, Humans, Male, Aged, Female, Middle Aged, Survival Rate, Disease-Free Survival, Antineoplastic Agents/administration & dosage, Chromosomes, Human, Pair 15/*genetics, Chromosomes, Human, Pair 17/*genetics, Leukemia, Promyelocytic, Acute/drug therapy/*genetics/*mortality, Oncogene Proteins, Fusion/*genetics, *Translocation, Genetic, Tretinoin/administration & dosage, fms-Like Tyrosine Kinase 3/*genetics",
author = "Susanne Schnittger and Ulrike Bacher and Claudia Haferlach and Wolfgang Kern and Tamara Alpermann and Torsten Haferlach",
year = "2011",
doi = "10.3324/haematol.2011.049007",
language = "English",
volume = "96",
pages = "1799--1807",
journal = "HAEMATOLOGICA",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "12",

}

RIS

TY - JOUR

T1 - Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA.

AU - Schnittger, Susanne

AU - Bacher, Ulrike

AU - Haferlach, Claudia

AU - Kern, Wolfgang

AU - Alpermann, Tamara

AU - Haferlach, Torsten

PY - 2011

Y1 - 2011

N2 - Combined treatment with all-trans-retinoic acid and chemotherapy is extremely efficient in patients with acute promyelocytic leukemia with t(15;17)/PML-RARA, but up to 15% of patients relapse.

AB - Combined treatment with all-trans-retinoic acid and chemotherapy is extremely efficient in patients with acute promyelocytic leukemia with t(15;17)/PML-RARA, but up to 15% of patients relapse.

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Survival Rate

KW - Disease-Free Survival

KW - Antineoplastic Agents/administration & dosage

KW - Chromosomes, Human, Pair 15/genetics

KW - Chromosomes, Human, Pair 17/genetics

KW - Leukemia, Promyelocytic, Acute/drug therapy/genetics/mortality

KW - Oncogene Proteins, Fusion/genetics

KW - Translocation, Genetic

KW - Tretinoin/administration & dosage

KW - fms-Like Tyrosine Kinase 3/genetics

KW - Adult

KW - Humans

KW - Male

KW - Aged

KW - Female

KW - Middle Aged

KW - Survival Rate

KW - Disease-Free Survival

KW - Antineoplastic Agents/administration & dosage

KW - Chromosomes, Human, Pair 15/genetics

KW - Chromosomes, Human, Pair 17/genetics

KW - Leukemia, Promyelocytic, Acute/drug therapy/genetics/mortality

KW - Oncogene Proteins, Fusion/genetics

KW - Translocation, Genetic

KW - Tretinoin/administration & dosage

KW - fms-Like Tyrosine Kinase 3/genetics

U2 - 10.3324/haematol.2011.049007

DO - 10.3324/haematol.2011.049007

M3 - SCORING: Journal article

VL - 96

SP - 1799

EP - 1807

JO - HAEMATOLOGICA

JF - HAEMATOLOGICA

SN - 0390-6078

IS - 12

M1 - 12

ER -